Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.

Literature DB >> 28074254

The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.

Roberto Vettor¹, Silvio E Inzucchi², Paola Fioretto³.

Abstract

Entities: Chemical Gene

Keywords: Cardiovascular disease; Empagliflozin; Heart failure; Mitochondrial function; NHE; SGLT2 inhibitors; Type 2 diabetes

Mesh：

Substances：

Year: 2017 PMID： 28074254 DOI： 10.1007/s00125-016-4194-y

Source DB: PubMed Journal: Diabetologia ISSN： 0012-186X Impact factor: 10.122

× No keyword cloud information.

22 in total

1. Eplerenone in patients with systolic heart failure and mild symptoms.

Authors: Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal: N Engl J Med Date: 2010-11-14 Impact factor: 91.245

Review 2. Defective mitochondrial biogenesis: a hallmark of the high cardiovascular risk in the metabolic syndrome?

Authors: Enzo Nisoli; Emilio Clementi; Michele O Carruba; Salvador Moncada
Journal: Circ Res Date: 2007-03-30 Impact factor: 17.367

Review 3. Cardiac metabolism in heart failure: implications beyond ATP production.

Authors: Torsten Doenst; Tien Dung Nguyen; E Dale Abel
Journal: Circ Res Date: 2013-08-30 Impact factor: 17.367

4. Glucagon in heart failure and in cardiogenic shock. Experience in 50 patients.

Authors: R Lvoff; D E Wilcken
Journal: Circulation Date: 1972-03 Impact factor: 29.690

5. Exercise training boosts eNOS-dependent mitochondrial biogenesis in mouse heart: role in adaptation of glucose metabolism.

Authors: Roberto Vettor; Alessandra Valerio; Maurizio Ragni; Elisabetta Trevellin; Marnie Granzotto; Massimiliano Olivieri; Laura Tedesco; Chiara Ruocco; Andrea Fossati; Roberto Fabris; Roberto Serra; Michele O Carruba; Enzo Nisoli
Journal: Am J Physiol Endocrinol Metab Date: 2013-12-31 Impact factor: 4.310

6. Haemodynamic effects of glucagon.

Authors: J G Murtagh; P F Binnion; S Lal; K J Hutchison; E Fletcher
Journal: Br Heart J Date: 1970-05

7. SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.

Authors: Muhammad Abdul-Ghani; Stefano Del Prato; Robert Chilton; Ralph A DeFronzo
Journal: Diabetes Care Date: 2016-05 Impact factor: 19.112

Review 8. Mitochondria in cardiac hypertrophy and heart failure.

Authors: Mariana G Rosca; Bernard Tandler; Charles L Hoppel
Journal: J Mol Cell Cardiol Date: 2012-09-13 Impact factor: 5.000

9. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.

Authors: Ele Ferrannini; Michael Mark; Eric Mayoux
Journal: Diabetes Care Date: 2016-07 Impact factor: 19.112

10. Empagliflozin decreases myocardial cytoplasmic Na⁺ through inhibition of the cardiac Na⁺/H⁺ exchanger in rats and rabbits.

Authors: Antonius Baartscheer; Cees A Schumacher; Rob C I Wüst; Jan W T Fiolet; Ger J M Stienen; Ruben Coronel; Coert J Zuurbier
Journal: Diabetologia Date: 2016-10-17 Impact factor: 10.122

11 in total

1. The bark giving diabetes therapy some bite: the SGLT inhibitors.

Authors: Sally M Marshall
Journal: Diabetologia Date: 2018-10 Impact factor: 10.122

2. Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

Authors: Di Zhao; Hui Liu; Pingshuan Dong
Journal: J Hum Hypertens Date: 2018-11-15 Impact factor: 3.012

Review 3. Mitochondrial dysfunction in pathophysiology of heart failure.

Authors: Bo Zhou; Rong Tian
Journal: J Clin Invest Date: 2018-08-20 Impact factor: 14.808

Review 4. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.

Authors: André J Scheen
Journal: Nat Rev Endocrinol Date: 2020-08-27 Impact factor: 43.330

5. Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial.

Authors: Gian Pio Sorice; Francesca Cinti; Lucia Leccisotti; Domenico D'Amario; Margherita Lorusso; Maria Angela Guzzardi; Teresa Mezza; Camilla Cocchi; Umberto Capece; Pietro Manuel Ferraro; Filippo Crea; Alessandro Giordano; Patricia Iozzo; Andrea Giaccari
Journal: Diabetes Ther Date: 2021-05-26 Impact factor: 2.945

6. Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects.

Authors: Ioanna Andreadou; Panagiotis Efentakis; Evangelos Balafas; Gabriele Togliatto; Constantinos H Davos; Aimilia Varela; Constantinos A Dimitriou; Panagiota-Efstathia Nikolaou; Eirini Maratou; Vaia Lambadiari; Ignatios Ikonomidis; Nikolaos Kostomitsopoulos; Maria F Brizzi; George Dimitriadis; Efstathios K Iliodromitis
Journal: Front Physiol Date: 2017-12-19 Impact factor: 4.566

7. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.

Authors: Hsiang-Chun Lee; Yi-Lin Shiou; Shih-Jie Jhuo; Chia-Yuan Chang; Po-Len Liu; Wun-Jyun Jhuang; Zen-Kong Dai; Wei-Yu Chen; Yun-Fang Chen; An-Sheng Lee
Journal: Cardiovasc Diabetol Date: 2019-04-01 Impact factor: 9.951